TheraSphere

Bruce Power to explore production of cancer-fighting medical isotope yttrium-90 for global distribution

Retrieved on: 
Monday, October 3, 2022
YouTube, Y-90, Cancer, Saugeen Ojibway Nation Territory, Liver cancer, Medicine, IPS, Society, Saugeen First Nation, LinkedIn, Business development, Ojibwe, Twitter, Interventional oncology, Instagram, Boston Scientific, MOU, Partnership, TheraSphere, SON, TC Energy, Leadership, Electricity, Environment, Microparticle, Patient, Power, Bruce Power, OMERS, GLOBE, Medical imaging, Lithium, Facebook, Isotope, Isogenic human disease models

Medical isotopes save lives and Ontario is primed to become an isotope superpower, said Ontarios Energy Minister Todd Smith.

Key Points: 
  • Medical isotopes save lives and Ontario is primed to become an isotope superpower, said Ontarios Energy Minister Todd Smith.
  • Additionally, Bruce Power will soon become the first nuclear power reactor operator to commercially produce lutetium-177 through an innovative Isotope Production System (IPS).
  • The IPS is a first-of-its-kind solution to produce short-lived medical isotopes in a commercial reactor and will provide unprecedented capacity, redundancy and scale for medical isotope production.
  • Isogen will also work with Bruce Power and Boston Scientific on the feasibility of yttrium-90 production using the IPS.

Boston Scientific Receives FDA Approval for TheraSphere™ Y-90 Glass Microspheres

Retrieved on: 
Thursday, March 18, 2021
Clinical medicine, Medicine, Medical specialties, TheraSphere, Hepatology, Interventional radiology, Hepatocellular carcinoma, Yttrium-90, Yttrium, Selective internal radiation therapy, SIR-Spheres

MARLBOROUGH, Mass., March 18, 2021 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma (HCC).

Key Points: 
  • MARLBOROUGH, Mass., March 18, 2021 /PRNewswire/ --Boston Scientific Corporation (NYSE: BSX) announced it has received U.S. Food and Drug Administration (FDA) approval of the TheraSphere Y-90 Glass Microspheres, developed for the treatment of patients with hepatocellular carcinoma (HCC).
  • TheraSphere treatment, a type of SIRT with low toxicity, is comprised of millions of microscopic glass beads containing radioactive yttrium (Y-90), which are delivered directly to liver tumors via catheter and result in minimal exposure to surrounding healthy tissue.
  • Approval of TheraSphere was based on results from the LEGACY study, designed to evaluate the safety and efficacy of the therapy for the treatment of early and advanced HCC.
  • Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world.

CIRT-EU Registry for SIR-Spheres® Therapy presented at CIRSE 2020 Summit

Retrieved on: 
Tuesday, September 15, 2020
Medicine, Clinical medicine, Physical sciences, SIR-Spheres, Sirtex, Selective internal radiation therapy, Radiation therapy, Yttrium-90, Yttrium, SIRT, Brachytherapy, TheraSphere

"I am extremely proud of the CIRSE team for their hard work the last six years to successfully complete this registry," said Helmberger.

Key Points: 
  • "I am extremely proud of the CIRSE team for their hard work the last six years to successfully complete this registry," said Helmberger.
  • CIRT EU is the largest observational registry run exclusively by CIRSE and funded by a grant provided by Sirtex Medical Europe.
  • Sirtex's current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres Y-90 resin microspheres.
  • Selective internal radiation therapy (SIRT) with SIR-Spheres Y-90 resin microspheres is a prescription device for the treatment of inoperable liver tumours.

CIRT-EU Registry for SIR-Spheres® Therapy presented at CIRSE 2020 Summit

Retrieved on: 
Tuesday, September 15, 2020
Medicine, Clinical medicine, Physical sciences, SIR-Spheres, Sirtex, Selective internal radiation therapy, Radiation therapy, Yttrium-90, Yttrium, SIRT, Brachytherapy, TheraSphere

"I am extremely proud of the CIRSE team for their hard work the last six years to successfully complete this registry," said Helmberger.

Key Points: 
  • "I am extremely proud of the CIRSE team for their hard work the last six years to successfully complete this registry," said Helmberger.
  • CIRT EU is the largest observational registry run exclusively by CIRSE and funded by a grant provided by Sirtex Medical Europe.
  • Sirtex's current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres Y-90 resin microspheres.
  • Selective internal radiation therapy (SIRT) with SIR-Spheres Y-90 resin microspheres is a prescription device for the treatment of inoperable liver tumours.

Sirtex Medical Launches State-of-the-Art SIROS™ System for Advanced SIR-Spheres® Resin Microspheres Delivery

Retrieved on: 
Monday, August 3, 2020
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Radiation therapy, Medicine, Physical sciences, Natural sciences, SIR-Spheres, Sirtex, Yttrium-90, Cancer, Yttrium, Selective internal radiation therapy, TheraSphere

Sirtex Medical US Holdings, Inc. (Sirtex), a leading manufacturer of targeted liver cancer therapies, announced the launch of SIROS , an innovative system for the delivery of SIR-Spheres Y-90 resin microspheres.

Key Points: 
  • Sirtex Medical US Holdings, Inc. (Sirtex), a leading manufacturer of targeted liver cancer therapies, announced the launch of SIROS , an innovative system for the delivery of SIR-Spheres Y-90 resin microspheres.
  • With the systems visually controlled administration, physicians can determine and adjust the precise quantity and speed of SIR-Spheres microspheres delivery.
  • Additionally, the system is designed to be simple to use yet versatile enough to allow expanded options for patient-tailored delivery.
  • Sirtexs current lead product is a targeted radiation therapy for liver cancer called SIR-Spheres Y-90 resin microspheres.

Recommendations for Personalised HCC Treatment With Y90 TheraSphere™ Published by an International Multidisciplinary Group

Retrieved on: 
Tuesday, July 23, 2019
Medicine, Medical specialties, Radiation therapy, Clinical medicine, Medical physics, Radiobiology, TheraSphere, Hepatology, Interventional radiology, Hepatocellular carcinoma, Embolization, Dosimetry

LONDON, July 23, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), a global healthcare company, today announced consensus recommendations for personalised treatment for hepatocellular carcinoma (HCC) with TheraSphere have been published by an international multidisciplinary working group1.

Key Points: 
  • LONDON, July 23, 2019 /PRNewswire/ -- BTG plc (LSE: BTG), a global healthcare company, today announced consensus recommendations for personalised treatment for hepatocellular carcinoma (HCC) with TheraSphere have been published by an international multidisciplinary working group1.
  • Higher response rates of 71% were seen in the personalised prospective dosimetry arm vs 36% with standard dosimetry.
  • "The working group reached a consensus recommendation on simple, reproducible and evidence-based practice for personalised treatment of HCC patients with TheraSphere.
  • We provide high value patient-centric treatment options which include locally-applied embolisation, radiotherapy with Y90 glass microspheres and cryoablation.

Recommendations for Personalised HCC Treatment With Y90 TheraSphere™ Published by an International Multidisciplinary Group

Retrieved on: 
Tuesday, July 23, 2019
Medicine, Medical specialties, Branches of biology, Medical physics, Radiobiology, Radiation protection, TheraSphere, Interventional radiology, Radiation therapy, Dosimetry, Embolization, Cryoablation

Higher response rates of 71% were seen in the personalised prospective dosimetry arm vs 36% with standard dosimetry.

Key Points: 
  • Higher response rates of 71% were seen in the personalised prospective dosimetry arm vs 36% with standard dosimetry.
  • "The working group reached a consensus recommendation on simple, reproducible and evidence-based practice for personalised treatment of HCC patients with TheraSphere.
  • For each scenario, recommendations are provided on patient selection, treatment planning and dosimetry, treatment delivery and outcome assessment and degree of recommendation and the strength of consensus.
  • We provide high value patient-centric treatment options which include locally-applied embolisation, radiotherapy with Y90 glass microspheres and cryoablation.